C4 Therapeutics, Inc. (CCCC)
| Market Cap | 267.85M |
| Revenue (ttm) | 35.95M |
| Net Income (ttm) | -104.99M |
| Shares Out | 97.58M |
| EPS (ttm) | -1.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,702,720 |
| Open | 2.830 |
| Previous Close | 2.830 |
| Day's Range | 2.730 - 2.940 |
| 52-Week Range | 1.210 - 3.820 |
| Beta | 2.86 |
| Analysts | Strong Buy |
| Price Target | 12.20 (+344.44%) |
| Earnings Date | May 6, 2026 |
About CCCC
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutat... [Read more]
Financial Performance
In 2025, C4 Therapeutics's revenue was $35.95 million, an increase of 1.02% compared to the previous year's $35.58 million. Losses were -$104.99 million, -0.31% less than in 2024.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for CCCC stock is "Strong Buy." The 12-month stock price target is $12.2, which is an increase of 344.44% from the latest price.
News
C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion
C4 Therapeutics said on Thursday it has entered into a deal focused on research and development of a type of cancer drug with Swiss drugmaker Roche that could be worth more than $1 billion.
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target C4T to Develop Degraders With Payload Properties; Roche to Conjugate Payloads to Targeted...
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
Novel Combination Regimen Positions Cemsidomide for Use in Earlier Lines of Therapy Novel Combination Regimen Positions Cemsidomide for Use in Earlier Lines of Therapy
C4 Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference
Cemsidomide is advancing in global Phase 2 and upcoming Phase 1B studies for multiple myeloma, showing strong efficacy and safety in heavily pretreated patients. The company’s robust pipeline, strategic partnerships, and financial runway support key milestones through 2028.
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,...
C4 Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The session highlighted a robust clinical and discovery pipeline, with cemsidomide positioned as a best-in-class IKZF1/3 degrader for myeloma. Key milestones include ongoing phase II and upcoming combination studies, a focus on regulatory rigor, and a strong safety-efficacy balance supporting accelerated approval prospects.
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Cemsidomide Advancing into Later-stage Development with Potential for Accelerated Approval; First Patient Dosed in the Phase 2 MOMENTUM Trial for Multiple Myeloma in the Fourth Line or Later Phase 1b ...
C4 Therapeutics to Participate in Upcoming March Conferences
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) sci...
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma
Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027 Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 WATERTOWN, Mass., Feb. 23, 2026...
C4 Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Cemsidomide is advancing to phase II and IB trials in myeloma, with MRD negativity as a key regulatory endpoint. Financing extends runway to 2028, supporting both single-agent and combination studies, while collaborations and a diversified pipeline underpin long-term strategy.
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) sci...
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026 Intern...
C4 Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Two clinical programs are advancing, with cemsidomide showing strong efficacy and safety in a highly refractory population and moving to phase two. Financial runway extends through 2028, with key data readouts and potential milestone payments expected. Combination studies and global expansion are underway.
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, ...
C4 Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
The discussion highlighted cemsidomide's strong safety and efficacy in relapsed/refractory myeloma, strategic plans for combination trials with BiTEs, and a robust financial runway through 2028. Market potential is estimated at $2.5–$4 billion as treatment paradigms evolve.
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceed...
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in ...
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma
WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, ...
C4 Therapeutics Transcript: Status Update
Cimcitamide demonstrated a strong safety and efficacy profile in heavily pretreated multiple myeloma patients, with durable responses and manageable neutropenia. Regulatory alignment supports a clear path to accelerated approval, with pivotal trials set to begin in 2026 and significant commercial potential projected.
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refr...
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,...
C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting
WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,...
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Cemsidomide Phase 1 Data in Multiple Myeloma Accepted as an Oral Presentation at the International Myeloma Society (IMS) Annual Meeting; As of the July 23, 2025, Data Cutoff, Phase 1 ORR Remains at 4...
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µ g...
C4 Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference
Significant progress was reported across three clinical programs, with cemsidomide showing best-in-class potential in myeloma and NHL, and CFT1946 and CFT8919 advancing with promising efficacy and safety. Multiple new studies and data readouts are planned for 2025 and beyond.